studies

A prospective cohort analysis of atypical femur fractures (AFF) in women from Kaiser Permanente Southern California (KPSC): identification of risk factors and construction of risk prediction models

The goals of this study are to develop multivariate risk prediction models to predict the 2-year risk of atypical femur fractures and 2-year risk of hip fracture. A secondary goal is to create a simple clinical tool that will allow clinicians and patients to estimate the risk of both types of fractures.

Principal Investigator:

Annette L. Adams, PhD, MPH

Funding Source:

Merck & Co., Inc.

Funding Years:

2016 - 2017

Femur Fracture Outcomes Associated with Bisphosphonate Use

The goals of this study are to examine the association between long-term bisphosphonate use patterns and subsequent risk of major osteoporotic fracture and to estimate the association between long-term bisphosphonate use patterns and subsequent risk of atypical femur fracture.

Site Principal Investigator:

Annette L. Adams, PhD, MPH

Funding Source:

National Institute on Aging (NIA)

Funding Years:

2015 - 2018

Fracture, Osteopenia, and CT Utilization Study (FOCUS Study)

The aim of this study is to validate within a population of KPSC patients the ability of a CT-based Biomechanical CT analysis to identify patients with osteopenia who are at high risk for hip fracture.

Principal Investigator:

Annette L. Adams, PhD, MPH

Funding Source:

Merck & Co., Inc.

Funding Years:

2015 - 2017

Fracture, Osteopenia, and CT Utilization Study (FOCUS Study)

The aim of this study is to validate within a population of KPSC patients the ability of a CT-based Biomechanical CT analysis to identify patients with osteopenia who are at high risk for hip fracture.

Principal Investigator:

Annette L. Adams, PhD, MPH

Funding Source:

Amgen, Inc.

Funding Years:

2016 - 2017

Predicting Two Year Risk of Major Osteoporosis-related Fractures

The primary objective of the study is to develop and validate clinical prediction models to estimate the 1-2 year risk of: (1) major osteoporosis-related fractures and (2) osteoporosis-related hip fractures.

Principal Investigator:

Annette L. Adams, PhD, MPH

Funding Source:

Amgen, Inc.

Funding Years:

2014 - 2017

Retrospective Cohort Study of Risk of Hip Fractures Associated with High Dose, Long-term Proton Pump Inhibitor (HD-PPI) Use and Cytochrome P450 Pharmacogenomics

The main goals of this study are to conduct two related cohort studies intended to address questions related to the association between PPI and HD-PPI use in a setting of complex medication usage patterns and to conduct a pharmacogenetics study exploring potential modification of the relationship between PPI use and hip fracture risk by CYP2C19 genotype.

Principal Investigator:

Annette L. Adams, PhD, MPH

Funding Source:

Food and Drug Administration (FDA)

Funding Years:

2014 - 2018

Studying the relationship of hyponatremia on bone disease, fractures, and fall risk

A cross sectional and longitudinal study that seeks to establish or determine a relationship between hyponatremia and bone density disorders (osteoporosis); hyponatremia and vertebral fractures; hyponatremia and risk of hip fractures.

Principal Investigator:

Annette L. Adams, PhD, MPH

Funding Source:

Otsuka America Pharmaceutical, Inc.

Funding Years:

2015